CODI alert issued for missing Roanoke teen
ROANOKE, Va. (WFXR) — Virginia State Police have issued a CODI alert on behalf of Roanoke City Police.
Brooklyn Gloria Walker is 13 years old, 4'11', with brown hair and blue eyes.
She was last seen on on Sunday, June 1, around 8:45 a.m. on 17th St. Southeast. VSP says she's believed to be on foot, and her disappearance poses a credible threat to her health and safety.
If you see Brooklyn, call 911.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
37 minutes ago
- News24
Body found in dam during search for missing Western Cape teen
While searching for a missing 16-year-old girl on Monday, Western Cape police officers recovered a body from a dam in Paarl. According to police spokesperson Warrant Officer Joseph Swartbooi, the body has not been identified. 'An autopsy will be conducted to determine the cause of death. Paarl police registered a murder for further investigation. The suspects are yet to be arrested,' he said. The discovery was made during a community-led search for Chanelle Plaatjies, who was last seen on 14 May. Rural and Farmworkers and Development Organisation spokesperson Billy Claasen believes the body, which was found near the Allandale Correctional Centre, could be that of the missing teen. But Swartbooi said: 'The circumstances surrounding the missing persons enquiry registered with Paarl East police on Wednesday for further investigation are still under investigation.' In February, the body of 17-year-old Ongeziwe Kamlana was found burnt beyond recognition in Kuils River. A 28-year-old man was arrested in connection with her murder The Gugulethu matric pupil's body was found two weeks after she was reported missing by her mother. She was last seen on her way home from extra classes at Fezeka Secondary School on 17 February.
News24
37 minutes ago
- News24
Kevin Costner sued for allegedly forcing a stuntwoman to perform violent rape scene
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once. Start your FREE trial now
Medscape
2 hours ago
- Medscape
GLP-1 Less Frequent Dosing May Maintain Weight Loss
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses. METHODOLOGY: GLP-1 RAs are transforming obesity treatment, but high costs and shortages limit patient access. Clinicians have suggested a less frequent dosing to maintain weight loss, but evidence supporting its effectiveness is lacking. Researchers used a combination of real-world case reports and mathematical modeling to examine the efficacy of a less frequent dosing of GLP-1 RAs for weight maintenance. They analyzed the data of two patients who used GLP-1 RAs at less frequent dosing schedules than recommended; patient 1 with obesity and prediabetes self-administered 7.5 mg tirzepatide every 10-14 days, whereas patient 2 with uncontrolled type 2 diabetes managed intermittent dosing of 15 mg tirzepatide due to supply shortages. A mathematical pharmacokinetic-pharmacodynamic model was used to simulate long-term changes in body weight of virtual patients administered semaglutide and tirzepatide at various dosing intervals. Simulations modeled semaglutide (2.4 mg) or tirzepatide (5 mg, 10 mg, or 15 mg) as a once-weekly dosing for 120 weeks, after which the 7-day dosing interval was increased to 10, 14, or 28 days or retained. TAKEAWAY: Patient 1 achieved an additional 13.7% body weight loss over 7 months and maintained it thereafter. Patient 2 lost 30% of her body weight and safely stopped insulin; even with intermittent dosing of tirzepatide, she retained a 22.8% body weight loss from baseline. Mathematical modeling predicted that switching from one dose per week to one dose every 2 weeks maintained 72% and 78% of the body weight loss achieved with 2.4 mg semaglutide and 15 mg tirzepatide, respectively. Even monthly dosing may have preserved half of the body weight loss achieved with weekly dosing, demonstrating that the reduction in efficacy was not proportional to the reduction in dosing frequency. IN PRACTICE: 'Future studies are needed to identify patient factors that predict a more favorable response to less frequent dosing of incretin mimetics and to examine the long-term clinical outcomes achieved through this approach compared with other off-ramping options (eg, switching to alternative AOMs [anti-obesity medications]),' the authors wrote. SOURCE: This study was led by Calvin C. Wu, Tono Health, Brooklyn, New York. It was published online in Obesity . LIMITATIONS: No limitations were provided for this study. DISCLOSURES: Two authors reported receiving funding from the National Science Foundation. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. Credit Lead image: KKfotostock/Dreamstime Medscape Medical News © 2025 WebMD, LLC Cite this: Edited by Javed Choudhury. GLP-1 Less Frequent Dosing May Maintain Weight Loss - Medscape - June 03, 2025.
